Lisdexamfetamine dimesylate
Vyvanse (lisdexamfetamine dimesylate) is a small molecule pharmaceutical. Lisdexamfetamine dimesylate was first approved as Vyvanse on 2007-02-23. It is used to treat attention deficit disorder with hyperactivity and binge drinking in the USA.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Vyvanse
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vyvanse | New Drug Application | 2019-10-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| attention deficit disorder with hyperactivity | EFO_0003888 | D001289 | F90 |
| binge drinking | — | D063425 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Lisdexamfetamine Dimesylate, Vyvanse, Takeda Pharms Usa | |||
| 7105486 | 2023-02-24 | U-727, U-842 | |
| 7223735 | 2023-02-24 | DP | |
| 7655630 | 2023-02-24 | DP | |
| 7659253 | 2023-02-24 | DS, DP | U-727 |
| 7659254 | 2023-02-24 | U-727, U-1034 | |
| 7662787 | 2023-02-24 | DP | |
| 7662788 | 2023-02-24 | U-727 | |
| 7671030 | 2023-02-24 | DP | U-727 |
| 7671031 | 2023-02-24 | U-727 | |
| 7674774 | 2023-02-24 | DP | U-727, U-842 |
| 7678770 | 2023-02-24 | U-727, U-842 | |
| 7678771 | 2023-02-24 | DP | U-727, U-842 |
| 7687466 | 2023-02-24 | DP | |
| 7687467 | 2023-02-24 | DP | U-727, U-842 |
| 7700561 | 2023-02-24 | DP | |
| 7713936 | 2023-02-24 | U-727 | |
| 7718619 | 2023-02-24 | DP | U-727, U-842 |
| 7723305 | 2023-02-24 | DP | U-727, U-842 |
HCPCS
No data
Clinical
Clinical Trials
103 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | 2 | 5 | 8 | 20 | 8 | 42 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 3 | 3 | 1 | — | 7 |
| Cognitive dysfunction | D060825 | G31.84 | — | — | — | 3 | 1 | 4 | |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | 1 | 1 | 1 | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | 2 | 1 | — | 3 |
| Traumatic brain injuries | D000070642 | S06 | — | — | 1 | 1 | — | 2 | |
| Autism spectrum disorder | D000067877 | F84.0 | — | — | — | 1 | — | 1 | |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | 1 | — | 1 |
| Cognition | D003071 | EFO_0003925 | — | — | — | 1 | — | 1 | |
| Menopause | D008593 | EFO_0003922 | N95 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | F14 | 2 | 2 | — | — | — | 3 | |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | 2 | — | — | — | 2 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 1 | 2 | — | — | — | 2 |
| Sleep deprivation | D012892 | F51.12 | — | 1 | — | — | — | 1 | |
| Bulimia nervosa | D052018 | EFO_0005204 | F50.2 | — | 1 | — | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 6 | — | — | — | — | 6 | ||
| Pediatric obesity | D063766 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tobacco use disorder | D014029 | F17 | — | — | — | — | 1 | 1 | |
| Bulimia | D002032 | F50.2 | — | — | — | — | 1 | 1 | |
| Feeding behavior | D005247 | — | — | — | — | 1 | 1 | ||
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | 1 | 1 | |
| Sleep | D012890 | GO_0030431 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LISDEXAMFETAMINE DIMESYLATE |
| INN | lisdexamfetamine |
| Description | Lisdexamfetamine is an amino acid amide. |
| Classification | Small molecule |
| Drug class | amfetamine derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)O.CS(=O)(=O)O.C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN |
Identifiers
| PDB | — |
| CAS-ID | 608137-32-2 |
| RxCUI | 700810 |
| ChEMBL ID | CHEMBL1201178 |
| ChEBI ID | — |
| PubChem CID | 11597698 |
| DrugBank | DB01255 |
| UNII ID | H645GUL8KJ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Vyvanse - Takeda
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Vyvanse - Shire
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,600 documents
View more details
Safety
Black-box Warning
Black-box warning for: Vyvanse
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,653 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more